Feasibility of incorporating genomic knowledge into electronic medical records for pharmacogenomic clinical decision support by Overby, Casey Lynnette et al.
PROCEEDINGS Open Access
Feasibility of incorporating genomic knowledge
into electronic medical records for
pharmacogenomic clinical decision support
Casey Lynnette Overby
1*, Peter Tarczy-Hornoch
1,2,3, James I Hoath
4, Ira J Kalet
1,3,4,5,6, David L Veenstra
7
From 2010 AMIA Summit on Translational Bioinformatics
San Francisco, CA, USA. 10-12 March 2010
Abstract
In pursuing personalized medicine, pharmacogenomic (PGx) knowledge may help guide prescribing drugs based
on a person’s genotype. Here we evaluate the feasibility of incorporating PGx knowledge, combined with clinical
data, to support clinical decision-making by: 1) analyzing clinically relevant knowledge contained in PGx knowledge
resources; 2) evaluating the feasibility of a rule-based framework to support formal representation of clinically
relevant knowledge contained in PGx knowledge resources; and, 3) evaluating the ability of an electronic medical
record/electronic health record (EMR/EHR) to provide computable forms of clinical data needed for PGx clinical
decision support. Findings suggest that the PharmGKB is a good source for PGx knowledge to supplement
information contained in FDA approved drug labels. Furthermore, we found that with supporting knowledge
(e.g. IF age <18 THEN patient is a child), sufficient clinical data exists in University of Washington’s EMR systems to
support 50% of PGx knowledge contained in drug labels that could be expressed as rules.
Introduction
With the promise of personalized medicine, there is a
push for genomics-based diagnostics to be incorporated
into clinical practice [1]. Genomic medicine is medical
practice that incorporates genomics-based diagnostics
and has the potential to facilitate personalized medicine.
In the pursuit of personalized medical practice, pharma-
cogenomic (PGx) information that may be incorporated
into guidelines for prescribing drugs based on a persons’
genotype, is of particular interest in this research. If
clinical data and PGx knowledge can be taken into
account to improve initial drug dosage for individuals,
improvements in patients’ outcomes may be achieved in
a cost-effective manner. Here we evaluate the feasibility
of incorporating PGx knowledge, combined with clinical
data to support clinical decision-making.
The objectives for our study were to: 1) Perform an
analysis of clinically relevant knowledge contained in
PGx knowledge resources; 2) Evaluate the feasibility of a
rule-based framework to support formal representation
of clinically relevant knowledge contained in PGx
knowledge resources; and, 3) Evaluate the ability of an
electronic medical record/electronic health record
(EMR/EHR) to provide computable forms of the clinical
data needed for PGx clinical decision support.
Related work
PGx has already entered into clinical practice [2]. Here,
we give an overview of some existing standards for pre-
senting external knowledge in EMRs; and, describe
some resources that provide evidence necessary for
making PGx-related decisions.
Just-in-time clinical decision support
There are several instances in which the just-in-time
metaphor has been used in the context of medical deci-
sion-making. One example is the Infobutton Manager
[3], an information resource that is accessed through a
clinical information system, anticipates clinician’sq u e s -
tions, and provides links to pertinent electronic
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nic health record (EHR) system [4], a Web-based inte-
grated interface that provides access to both patient
specific information and knowledge resources that con-
tain information such as drug reference information and
clinical guidelines. Both of these approaches provide
point-of-care access to knowledge, and both focus on
methods for automatically selecting and retrieving
appropriate knowledge resources. The MINDscape sys-
tem, developed at the University of Washington (UW),
is of particular relevance to this research. We will use
this system as an example EHR framework against
which we will evaluate the feasibility of incorporating
PGx knowledge for clinical decision support. In this
study we analyze PGx knowledge resources including
PharmGKB [5], FDA approved drug labels [6], and rele-
vant biomedical literature. Objectives 2 and 3 focus on
characterizing PGx knowledge contained in drug labels
in particular.
Existing pharmacogenomic knowledge resources
The pharmacgenetics and pharmacogenomics knowl-
edge base (PharmGKB, http://www.pharmgkb.org) is an
online, publicly available, resource that contains multiple
forms of curated PGx information to generate knowl-
edge of relationships among genes, drugs, and diseases.
Of interest to this work are the curated publications
containing evidence to support relationships; informa-
tion concerning the effects of genetic variation on rela-
tionships; and, drug-centered pathways connecting
genes involved in pharmacokinetics (PK) and pharmaco-
dynamics (PD) with highly curated knowledge and pri-
mary data [7].
There are three studies to date that have examined the
availability of PGx information in drug labels [8-10]. In
2006, researchers reported a lack of specific PGx-based
recommendations for prescribing and dosing of drugs
[8]. Of the top 200 prescribed drugs, they found that
71.3% had published PGx information in the literature,
but only three had package inserts with PGx informa-
tion sufficient to guide individualized dosing. In a 2008
study, authors reported that although there remains a
gap between published information on PGx and PGx
information found in labels, drug approvals have
recently included more PGx information [10]. In the
analysis, they demonstrate that one fourth of all pre-
scriptions are for drugs that contain PGx information in
their labeling. There are now a small number of pro-
ducts in the United States for which the FDA have asso-
ciated mandatory or recommended genetic tests [6].
Within the product labels, the listed drugs have PGx
information under several sections including: “Clinical
Pharmacology,”“ Indications and Usage,”“ Warnings or
Precautions,” and/or “Dosage and Administration.”
Methods
Toward our goal to analyze the feasibility of represent-
ing existing PGx knowledge for clinical decision support
in computable form, we had three objectives. Specific
methods for each objective are described below.
Availability of clinically relevant knowledge
For our first objective, we perform an analysis of clini-
cally relevant information contained in PGx knowledge
resources. Specifically, we review the drug labels of 28
p r i m a r yd r u g sf r o mt h eF D A“Table of valid genomic
biomarkers in the context of approved drug labels”
(FDA biomarker-drug pairs) [6]; the supporting refer-
ences listed for each FDA biomarker-drug pair; refer-
ences identified in PharmGKB that contain evidence of
the biomarker-drug relationship; and, the types of elec-
tronically available knowledge produced by the FDA and
contained within PharmGKB.
For each drug, we record the associated publications
containing evidence of biomarker-drug relationships on
the FDA website and within PharmGKB and determine
the degree of overlap of evidence coverage in these
resources. In addition, for each drug we catalogue the
curated knowledge contained in PharmGKB. Forms of
curated knowledge defined by PharmGKB include: cate-
gories of evidence, pathway evidence, variant evidence, gen-
otypedata, phenotype data,a n dclinical PGx section [5].
The PGx literature is curated using five categories of
evidence and standardized vocabularies of genes, drugs
and diseases. These categories include: clinical outcome
(CO); pharmacodynamics (PD); pharmacokinetics (PK);
molecular and cellular functional assays (FA); and, geno-
type (GN). In the PGx literature, CO, PD, PK and FA
are forms of phenotypic evidence. Pathway evidence
includes knowledge of biochemical pathways associated
with the use of a particular medication. Variant evidence
includes knowledge of genetic variants associated with
individual response to therapy. Genotype and phenotype-
data designate the existence of these types of data. Clin-
ical PGx section designates drugs for which all related
knowledge has been compiled within PharmGKB.
We classify electronically available knowledge as
encoded, tagged, or computable. Encoded and tagged
information may be described as computer accessible,
and computable knowledge as computer-readable. An
example of tagged information w o u l db eaw i k ip a g e
that contains a table of contents. The information on
the wiki page is free text, but tagged for particular sec-
tions identified in the table of contents. Resources con-
taining encoded information utilize controlled
vocabularies in order to add structure to information
and facilitate more complex computer access. For exam-
ple, PubMed contains encoded information about publi-
cation authors, titles, journals, etc. A user is then able to
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plex queries across all publications. Computable knowl-
edge is knowledge described in a language for
communication with the computer. If knowledge is
computable, then it can be described as an algorithm or
rule, and implemented as such in a computer program
or application. We discuss some of the steps taken to
translate PGx knowledge into computable form in the
next section.
Feasibility of rule-based representation
For our second objective, we evaluated the feasibility of
representing PGx knowledge in a computable form, sui-
table to code within an EHR framework. In our previous
objective, we catalogued the different types of electroni-
cally available knowledge produced by the FDA and
contained in PharmGKB. Steps required to translate
knowledge encoded in the PharmGKB into a computa-
ble form would differ from steps to translate FDA drug
label content, due to differences in the type of informa-
tion represented and the form in which it is captured
(i.e. free text, tagged, encoded).
For example, encoded knowledge about enzyme sub-
strates contained in PharmGKB (e.g. S-Warfarin is a
substrate of CYP2C9) could be utilized in a clinical deci-
sion support rule or in an algorithm. With supplemental
knowledge about CYP2C9 variants (e.g. CYP2C9*2 and
CYP2C9*3 variants are associated with impaired sub-
strate metabolism); and drug specific knowledge (e.g.
When taking Warfarin, decrease in S-warfarin clearance
is associated with increased bleeding risk), we can define
decision support rules such as “IF patient is taking War-
farin AND patient has CYP2C9*2 or CYP2C9*3 variants,
THEN there will be a decrease in S-warfarin clearance
AND there is an increased bleeding risk.” However, here
we focus on FDA drug labels because they are created
to provide clinical guidance, and are therefore more
likely to contain all of the knowledge necessary to define
a clinical decision support rule.
For the 28 drug labels of the FDA biomarker-drug
pairs, we identified passages containing clinically rele-
vant knowledge that may support PGx clinical decisions;
and, wherever feasible, translate passages into an if-then
rule representation. PGx knowledge contained in drug
labels are primarily in free-text form, therefore these
steps are performed manually.
In addition, we cluster PGx knowledge into general
categories and determine the type of user interface (UI)
presentation that would be appropriate. An example
category may be knowledge that provides support for
determining “who should be screened for a genetic var-
iant prior to administering a particular treatment.” UI
presentation types characterize how actionable a then
statement is, of an if-then rule. Types include:
information only; recommendation; and, warning alert.
A statement is classified as information only if no direct
action is specified within the statement, or actions are
specified using language with a low degree of certainty
(i.e. might, may, could). Conversely, a statement is clas-
sified as a recommendation if a clear action is specified
using language with a medium to high degree of cer-
t a i n t y( i . e .s h o u l d ,w i l l ,a r e ,i s ,m u s t ,w a s ,d o ) ;a n da sa
warning if potential consequences are specified (lan-
guage may be of any degree of certainty). In cases where
a statement falls into multiple categories, a choice is
made according to the following prioritization: warning,
or information, or recommendation. That is, if a state-
ment is identified as being both a recommendation and
a warning, it is classified as a warning. Similarly, if a
statement is identified as both information only and a
recommendation, it is classified as a recommendation.
Each designation refers to the type of presentation that
is appropriate given how actionable the if-then rule.
Availability of computable patient data
For our final objective, we evaluated the ability of an
EMR to provide in computable form (not free text) clin-
ical data needed for PGx clinical decision support. Parti-
cularly, we looked at data available in the UW
MINDscape EHR system, including laboratory systems
(pathology and microbiology), and performed the fol-
lowing steps for each of the if-then rules we identify in
Objective 2: 1) determine the types of clinical data
needed in combination with PGx knowledge to provide
clinical decision support; 2) determine whether or not
different types of data are already captured as discrete
data in the EMR; and, 3) for clinical data that are not
currently captured, estimate the feasibility of capturing
these data by expert opinion.
As an example, clinical data needed for the Warfarin
rule, described in the previous section, would be the
inclusion (or considering the inclusion) of Warfarin on
ap a t i e n t s ’ medication list; and, CYP2C9 variant status.
In some cases, our ability to utilize clinical data might
depend on the existence of supporting knowledge. For
example, with the statement “the patient is a poor meta-
bolizer of CYP2C9,” supporting knowledge must define
the CYP2C9 genotype that would classify a patient as “a
poor metabolizer of CYP2C9,” (e.g. IF patient has geno-
type CYP2C9*2/*3 THEN the patient is a poor
metabolizer).
Lastly, given the availability of clinical data and the if-
then rules that represent clinically relevant PGx knowl-
edge that we identify, we evaluate the ability for these
rules to be executed in the UW clinical care environ-
ment. For each if-then rule we determined whether all
clinical data needed to execute the rule exists as discrete
data. Cases where all data needs are satisfied can be
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cases where all data needs are not met, we evaluated the
feasibility of including the required clinical data. Clinical
data types considered most feasible to include within
the UW EHR framework by expert opinion are: disease
status definitions; data fields in pathology laboratory sys-
tems; data fields in microbiology laboratory systems; and
pathology or microbiology laboratory values that exist in
free text and can be parsed without use of full natural
language processing (NLP) methods. “Feasible expan-
sion” represents the inclusion of these clinical data types
within the UW EMR system. When appropriate, initially
unsatisfied clinical data needs can be categorized as
satisfied with “feasible expansion” of the UW EMR
system.
Results
Results of the evaluation across three objectives are
described below.
Availability of clinically relevant knowledge
R e l a t e dt oo u rf i r s to b j e c t ive, we found that there
was little overlap between references containing evi-
dence of biomarker-drug relationships: 1) identified
b yt h eF D A ;a n d ,2 )i d e n t i f i e dw i t h i nP h a r m G K B .
There were 185 articles containing evidence listed on
the FDA website and 268 articles with evidence of
biomarker-drug relationships of interest contained in
the PharmGKB. Only 28 (6.4%) of the total set of
articles containing evidence were found in both the
PharmGKB database and on the FDA website. Of the
28 contained in both resources, 11 (39%) were not
designated as containing evidence of the particular
drug-biomarker relationship of interest in
PharmGKB.
In addition, of the 251 publications in PharmGKB that
do not overlap with those listed by the FDA, the repre-
sentation of categories of evidence for biomarker-drug
relations are as follows: CO – 49(19%); PD – 80(32%);
PK – 141(56%); FA – 27(11%); and, GN – 171(68%).
These designations of “evidence categories” may be use-
ful for expanding upon the repository of biomedical lit-
erature containing knowledge to support PGx clinical
decisions.
In our evaluation of electronically available knowledge
for drug labels and relevant literature, we found that all
but one drug label (Codeine sulfate) could be located in
the DailyMed online database [11]. DailyMed contains
electronically available knowledge in which drug label
sections are tagged, but data are still in free text. In
addition to DailyMed drug sections, PharmGKB could
be a useful source of PGx knowledge relevant to guide
the use of each drug. Table 1 displays types of encoded
knowledge available for each drug.
Overall, we found that PharmGKB is a good supple-
ment to FDA approved drug label contents. PharmGKB
contains encoded knowledge from a large number of
publications that may provide additional evidence to
support PGx relationships contained in drug labels.
However, this knowledge is not currently in a computa-
ble format. In objective 2, we explore our ability to
represent PGx knowledge in a format suitable to code
within an EHR framework.
Feasibility of rule-based representation
Related to our second objective, from the 28 drug labels
r e v i e w e d ,w ew e r ea b l et oi d e n t i f y7 9p a s s a g e sc o n t a i n -
ing knowledge to support PGx clinical decisions. We
were able to translate all but 2 passages into one or
more decision support rules. In total, we defined 106 if-
then rules to support PGx clinical decisions based on
currently recommended FDA PGx testing.
In further evaluation we found that, given the status of
a patient with respect to a biomarker, 50% of all approx-
imate decision support rules help clinicians make deci-
sions about dose adjustments; help clinicians determine
appropriate patient monitoring requirements; and/or
illuminate certain considerations (e.g. risk of adverse
drug events, or potential altered response) before initiat-
ing therapy. In addition, 24% of the rules provide advice
on who will or will not benefit from treatment; 13%
provide advice related to testing (e.g. “how should test
results be interpreted”); 9% provide advice on coadmi-
nistration of medications (e.g. “for what types of drugs
should coadministration be approached with caution”);
and, 4% provide advice on what information related to
treatment should be relayed to the patient (See Figure 1
for details on categories of clinical decision support pro-
vided by rules).
Furthermore, we determined the type of UI presenta-
tion that would be appropriate for each rule. We found
that 39% should be presented as information only; 39%
should be presented as a recommendation; and, 22%
should be presented as a warning (See Table 2 for
examples, and Figure 1 for details on representation of
presentation types within various categories of support).
Availability of computable patient data
Related to our third objective, given the current avail-
ability of clinical data, we found that 32% of our 106 if-
then rules could be expressed without additional sup-
porting knowledge or information contained in clinical
notes (See Figure 2). The addition of supporting knowl-
edge would raise the percentage of rules with sufficient
clinical data access to 50%. We also determined, by
expert opinion, the feasibility of expanding the current
UW EMR system to incorporate data fields that allow
for the execution of PGx clinical decision support rules.
Overby et al. BMC Bioinformatics 2010, 11(Suppl 9):S10
http://www.biomedcentral.com/1471-2105/11/S9/S10
Page 4 of 9We considered “feasible expansion” to be the addition of
disease status definitions (11%); the addition of data
entry fields in pathology laboratory systems (<1%); the
addition of data fields in microbiology laboratory sys-
tems (20%); and, the ability to parse (not by full natural
language processing) pathology or microbiology labora-
tory values that exist in free text (7%). Percentages des-
ignate instances within the full set of if-then rules for
which lack of access to these definitions/fields would
inhibit our ability to execute rules. We found that with
feasible expansion to the current EMR system, sufficient
clinical data access for our if-then rules would increase
to 89%.
Limitations
Definitions and assignments of if-then rules into general
categories (as described in the methods for Feasibility
of Rule-based Representation section), were performed
b yas i n g l ea u t h o r .W ee v a l u a t et h ec o n s i s t e n c yo f
assignments through informal review of classifications
by all authors. While assignments are generally agreed
upon, in order to establish interrater reliability we
w o u l dn e e dt oa s s e s sa g r e e m e n ta m o n gm u l t i p l ep e r -
sons’ assigning if-then rules to the various categories.
Discussion
Overall, we found that our research findings will be use-
ful for designing a model to incorporate PGx knowledge
into EMR systems for clinical decision support. In our
first objective, we evaluated PharmGKB and FDA drug
labels as potential sources for PGx knowledge in the
context of clinical practice, and found that PharmGKB
might be a good supplement to FDA drug labels as a
source for evidence to support PGx clinical decisions.
However, PGx knowledge encoded in PharmGKB
alone might not be considered enough evidence to
guide clinical decisions. An evidence-based process
incorporating rigorous evidence review strategies [12]
Table 1 Types of encoded knowledge in PharmGKB
pathway evidence variant evidence genotype data phenotype data clinical PGx section
Abacavir xx
Atomoxetine
Atorvastatin xx x
Azathioprine xxx x
Busulfan
Capecitabine x
Carbamazepine xx
Celecoxib xx
Cetuximab x x
Clopidogrel xx x
Codeine sulfate xx
Dasatinib x
Erlotinib xx
Fluoxetine HCL xx x
Imatinib mesylate xx x
Irinotecan xx x xx
Isoniazid x
Lenalidomide
Maraviroc
Nilotinib
Panitumumab x
Prasugrel
Primaquine
Pyrazinamide x
Rasburicase x
Rifampin xx x x
Trastuzumab xx
Valproic acid x x
Voriconazole
Warfarin xx x xx
Types of PharmGKB encoded knowledge for medications that also contain PGx knowledge in their drug labels.
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Depending on the strength of evidence, a choice must
be made between providing information only; presenting
a warning; or, recommending an action. An approach to
clarifying the strength of evidence might be to incorpo-
rate the opinions of clinical and drug experts. For exam-
ple, recent work with the Drug-Interaction Knowledge
Base (DIKB) incorporates an evidential approach to
knowledge representation [13]. They combine an evi-
dence taxonomy containing 36 evidence types (e.g. ret-
rospective studies, clinical trials, metabolic inhibition
identification, etc.) with a set of inclusion criteria. When
given a specific set of evidence, the inclusion criteria
enables drug experts to specify their confidence level in
a drug mechanism assertion. Such an approach might
also be applied more generally to presenting PGx
k n o w l e d g ew i t h i na nE M R ,a l t h o u g hi n t e g r a t i o nw i t h
existing evidence-based processes used by healthcare
systems that utilize the EMR would be an essential com-
ponent of the implementation of this system.
In support of PharmGKB as a supplemental source for
clinical evidence, previous work shows that PharmGKB
can facilitate the assessment of the clinical validity and
utility of PGx tests through the identification of relevant
peer-reviewed manuscripts [14]. Manuscripts included
in PharmGKB are compared against those used in eva-
luations performed by professional organizations like
EGAPP (Evaluation of Genomic Applications in Practice
and Prevention) and ACCE (Analytic validity, Clinical
validity, Clinical utility, and Ethical, legal, and social
implications). Manuscripts included as primary data
sources in EGAPP and ACCE reviews were considered
to be prototypical. Similarly, in addition to drug labels,
professional organizations such as these are good
sources for clinical guidance for using PGx knowledge.
The organizations ascertain whether or not there is suf-
ficient evidence to support the use of PGx tests in clini-
cal practice by expert opinion. A recent example is a
statement from the American Society of Clinical Oncol-
ogy (ASCO) that recommends KRAS screening prior to
initiating anti-epidermal growth factor receptor mono-
clonal antibody therapy (e.g. Cetuximab) [15].
In our second and third objectives, we focused on
drug labels that contain PGx knowledge. We presented
as c h e m ef o rt r a n s l a t i n gP G xk n o w l e d g ei n t oi f - t h e n
rules, a format suitable to code within an EHR frame-
work; we evaluated the current state of PGx knowledge
(i.e. how mature/actionable); and determined whether
EMRs have the right data to support the execution of
rules for PGx clinical decision support. We found that
Figure 1 General and sub- categories of clinical decision support. Counts for if-then rules clustered into general and sub- categories; and
representation of UI classifications (information only, recommendation, and warning alerts) within each category.
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Approximate decision support rule Inpatient/
Outpatient
DB
Laboratory DB Supportive
Knowledge
Information/
Recommendation/
Warning
IF the patient has ASM AND the patient has a tumor with a
D816V c-Kit mutation THEN recommended dose of Gleevec
is 400 mg/day
Medication –
Imatinib
mesylate
(Gleevec®)
Disease status
– ASM, DFSP,
or GIST
Tumor/Pathogen genotype –
gastrointestinal stromal tumor
c-Kit expression
N/A Recommendation
IF the patient has a CYP2C9 variant AND the variant causes
poor metabolism THEN the dose of Celecoxib should be
reduced by 50%
Medication –
Celecoxib
CYP2C9 variant status CYP2C9 variants
causing poor
metabolism
Recommendation
IF the patient has a CYP2C19 variant AND the variant
causes poor metabolism THEN the dose adjustment for
Clopidogrel is unknown for the patient
Medication –
Clopidogrel
(Plavix®)
CYP2C19
variant status
CYP2C19 variants
causing poor
metabolism
Information
IF the patient has hepatic impairment OR the patient is
taking a medication that is a strong CYP2D6 inhibitor OR
the patient is a CYP2D6 poor metabolizer THEN the dose
of Atomoxetine should be adjusted
Disease status
– hepatic
impairment
Medication –
Atomoxetine
Medication list
CYP2D6
variant status
Medications
that are CYP2D6
inhibitors
CYP2D6 variants
causing poor
metabolism
Information
IF the patient will be taking Fluoxetine AND the patient is
taking other drugs that are metabolized by CYP2D6, THEN
coadministration should be approached with caution
Medication –
Fluoxetine
HCL
(Prozac®)
Medication list
N/A Medications
metabolized
by CYP2D6
Warning
Example if-then rules for PGx clinical decision support.
Figure 2 Clinical data access for rule execution. Both “EMR alone” and “EMR + supported knowledge” represent accessible clinical data within
an EMR. Supporting knowledge defines classifications such as “IF age < 18 THEN patient is a child.”
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EMR environment given the current availability of clini-
cal data and with the addition of supporting knowledge;
however, the maturity of the knowledge differs. Warning
and recommendation alert messages are appropriate for
22% and 39% (respectively) of all rules derived from
drug labels containing PGx knowledge. Even then, the
level of certainty expressed in the language used in
these statements varies.
Another interesting finding from our final objectives
was that only 13% of the rules we define represent
knowledge about when to perform a genetic test or how
to interpret test results. Therefore, in addition to
PharmGKB, resources such as the GeneReviews Knowl-
edge Base (genetests.org) [16] might also be considered
as a potential resource to supplement PGx knowledge
contained in drug labels.
While results from these objectives may differ between
institutions, we believe our methods are generalizable
and can be used to evaluate the availability of clinical
data to support PGx clinical decision support within any
EHR framework. Also, it has been shown that different
representations of PGx test results (e.g. gene single
nucleotide polymorphisms, gene alleles) with automated
interpretation (e.g. ‘homozygous normal’, ‘heterozygous
affected’) can be used effectively within the EMR with-
out impacting reaction times in responding to alert mes-
sages [17]. Therefore, we believe our methods are
applicable independent of PGx data representation.
Our findings form the basis for future work wherein
we will implement if-then rules electronically. As an
important caveat, although recent studies have shown
computerized alerts to be non-disruptive to the work-
flow of clinicians [18], alerts that raise frequent or insig-
nificant alarms will likely be ignored [19,20]. Therefore,
choice of triggers (clinical events that cause rules to be
invoked) and rules to execute in the context of an EMR
environment should be approached with care.
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